Oktolipen 600 mg, 30 pcs.

Active substance :

thioctic acid (a-lipoic acid) - 600 mg; 

Excipients:

 low substituted hyprolose (hydroxypropyl cellulose low substituted L-HPC LH-B1) - 120.90 mg;

hyprolose (hydroxypropyl cellulose (Klucel EF)) - 32.04 mg;

colloidal silicon dioxide (aerosil) - 24.03 mg;

magnesium stearate - 24.03 mg; 

Shell :

Opadry yellow (OPADRY 03F220017 Yellow) - 28.00 mg [hypromellose (hydroxypropyl methylcellulose), macrogol-6000 (polyethylene glycol 6000), titanium dioxide, talc, quinoline yellow aluminum varnish (E104), iron dye oxide yellow (E172)]

Oktolipen - a metabolic agent, is an endogenous antioxidant that binds free radicals.

Thioctic acid (alpha-lipoic acid) - an endogenous antioxidant (binds free radicals), is formed in the body during the oxidative decarboxylation of alpha-keto acids.

As a coenzyme of mitochondrial multienzyme complexes, it participates in the oxidative decarboxylation of pyruvic acid and alpha-keto acids. It helps to reduce the concentration of glucose in the blood and increase the glycogen content in the liver, as well as to overcome insulin resistance.

The nature of the biochemical action is close to the B vitamins.

Participates in the regulation of lipid and carbohydrate metabolism, stimulates cholesterol metabolism, improves liver function.

It has hepatoprotective, hypolipidemic, hypocholesterolemic, hypoglycemic effect. Improves trophic neurons and axonal conduction, reduces the manifestations of diabetic and alcoholic polyneuropathy.

Diabetic polyneuropathy; alcoholic polyneuropathy.

• hypersensitivity to the components of the drug;
• children under 18 years of age (efficacy and safety of use have not been established);
• pregnancy and the period of breastfeeding.

From the digestive system: symptoms of dyspepsia (including nausea, vomiting, heartburn).

On the part of the metabolism: symptoms of hypoglycemia (due to improved glucose uptake).

Allergic reactions: urticaria, systemic allergic reactions (including anaphylactic shock).

Thioctic acid (as a solution for infusion) reduces the effect of cisplatin.

With simultaneous use with insulin and / or oral hypoglycemic agents, an increase in the hypoglycemic effect is observed.

Thioctic acid forms difficult soluble complex compounds with sugar molecules. The prepared solution is incompatible with a solution of glucose, levulose, Ringer's solution, as well as with compounds (including their solutions) that react with disulfide and SH groups.

Inside, on an empty stomach, 30 minutes before a meal, without chewing, drinking plenty of fluids with 1 tablet (600 mg) once a day.

In some cases, for more effectiveness, the appointment of step therapy is recommended: the start of treatment is the intravenous administration of the drug Okolipen® in the form of a solution for infusion (2-4 weeks) with the subsequent transfer of the patient to the oral form of the drug. The type and duration of the course of therapy is determined by the doctor.

Symptoms: headache, nausea, vomiting.

Treatment: symptomatic. There is no specific antidote.

In patients with diabetes mellitus, especially at the beginning of treatment with Oktolipen, frequent monitoring of blood glucose concentration is necessary. In some cases, a dose reduction of hypoglycemic agents is required.

During treatment, it is necessary to strictly refrain from drinking alcohol, as ethanol reduces the therapeutic efficacy of thioctic acid.

pills